JP2008521906A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521906A5
JP2008521906A5 JP2007544439A JP2007544439A JP2008521906A5 JP 2008521906 A5 JP2008521906 A5 JP 2008521906A5 JP 2007544439 A JP2007544439 A JP 2007544439A JP 2007544439 A JP2007544439 A JP 2007544439A JP 2008521906 A5 JP2008521906 A5 JP 2008521906A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
transglucosidase
group
peptidase
amylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007544439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521906A (ja
Filing date
Publication date
Priority claimed from US11/000,668 external-priority patent/US20060115467A1/en
Application filed filed Critical
Publication of JP2008521906A publication Critical patent/JP2008521906A/ja
Publication of JP2008521906A5 publication Critical patent/JP2008521906A5/ja
Pending legal-status Critical Current

Links

JP2007544439A 2004-12-01 2005-11-30 自閉症の治療用の組成物及び方法 Pending JP2008521906A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/000,668 US20060115467A1 (en) 2004-12-01 2004-12-01 Compositions and methods for the treatment of autism
PCT/US2005/043175 WO2006060414A2 (en) 2004-12-01 2005-11-30 Compositions and methods for the treatment of autism

Publications (2)

Publication Number Publication Date
JP2008521906A JP2008521906A (ja) 2008-06-26
JP2008521906A5 true JP2008521906A5 (enExample) 2008-12-18

Family

ID=36565652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007544439A Pending JP2008521906A (ja) 2004-12-01 2005-11-30 自閉症の治療用の組成物及び方法

Country Status (8)

Country Link
US (2) US20060115467A1 (enExample)
EP (1) EP1817052A4 (enExample)
JP (1) JP2008521906A (enExample)
CN (1) CN101287829A (enExample)
AU (1) AU2005311975A1 (enExample)
CA (1) CA2590384A1 (enExample)
WO (1) WO2006060414A2 (enExample)
ZA (1) ZA200704677B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
SI2016838T1 (en) * 2007-06-18 2018-01-31 Et & Ds Company Ltd Food supplement
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
MX2010011797A (es) * 2008-04-30 2010-11-30 Danisco Inc Proceso de fermentacion mejorado el cual usa melazas.
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es) * 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
NZ593831A (en) 2009-01-06 2013-09-27 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
KR20170005191A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2010147714A1 (en) * 2009-06-16 2010-12-23 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
US9931381B2 (en) * 2009-11-23 2018-04-03 Prothera, Inc. Methods of comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
WO2012145651A2 (en) 2011-04-21 2012-10-26 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
WO2013103746A1 (en) * 2012-01-03 2013-07-11 Curemark, Llc Methods of treating behavioral symptoms of neurological and mental disorders
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10195256B2 (en) 2015-12-14 2019-02-05 Thea Fournier Enzyme formulation for reducing salicylate and other intolerance
US9775887B2 (en) * 2015-12-14 2017-10-03 Thea Fournier Enzyme formulation for reducing salicylate intolerance
CN105652016A (zh) * 2016-01-28 2016-06-08 深圳大学 一种孤独症检测标志物及其检测方法
GB201614415D0 (en) 2016-08-24 2016-10-05 Pepsis Ltd Enzymes for the treatment of human enterometabolic dysfunction
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
TWI658791B (zh) * 2017-09-25 2019-05-11 愛之味股份有限公司 具有調節血脂、改善腸道菌叢及提升免疫力功能的富含寡醣乳製品及其製法
US12152261B2 (en) * 2019-02-19 2024-11-26 Dsm Ip Assets B.V. Method for reducing fructan in a food product with aid of invertase (EC 3.2.1.26)
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2023115212A1 (en) * 2021-12-23 2023-06-29 Access Nutrients Inc. Prevention and treatment of diseases using phytase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042823A (en) * 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US6783757B2 (en) * 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions

Similar Documents

Publication Publication Date Title
JP2008521906A5 (enExample)
Naveed et al. Protease—a versatile and ecofriendly biocatalyst with multi-industrial applications: an updated review
US20080199448A1 (en) Enzyme composition for improving food digestion
ATE473010T1 (de) Enzyme für pharmazeutische anwendung
JP5448162B2 (ja) 酵素を利用したバイオフィルム形成の防止とその制御
EP2099466B1 (en) Use of hydrolytic and oxidative enzymes to dissolve biofilm in ears
ATE481883T1 (de) Milchfreie milchersatzprodukte
RU2007149045A (ru) Липазы для фармацевтического применения
Kaur et al. Enzymes as drugs: an overview.
MX2007013725A (es) Produccion de beta-glucanos y mananos.
RU2008102650A (ru) Амилазы для фармацевтического применения
WO2008021987A3 (en) Proteolytic enzyme formulations
DE50002450D1 (de) Enzyme zur behandlung von diabetes mellitus typ i
RU2001126526A (ru) Лекарственное средство, предназначенное для лечения диабета
NZ623123A (en) A process for concentration of a polypeptide
WO2009111083A2 (en) In vivo temporal control of activ at able matrix- degrading enzymes
WO2003012071A3 (en) Nucleic acids of aspergillus fumigatus encoding industrial enzymes and methods of use
MX2009006597A (es) Variantes de lipasa para uso farmaceutico.
WO2002074895A3 (en) Fermentation process including the use of enzymes
WO2002008404A3 (en) Production of lysosomal enzymes in plants by transient expression
JP2019534691A5 (enExample)
BR0314435A (pt) Utilização de enzimas da famìlia 8 com atividade xilanolìtica na cozedura
Wang et al. An acidophilic β-galactosidase from Bispora sp. MEY-1 with high lactose hydrolytic activity under simulated gastric conditions
Kunamneni et al. Enzymes as therapeutic agents
AU2366602A (en) Use of enzymes obtained from ciliates as medicaments for promoting digestion